These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 16350674)

  • 1. Diabetes and heart failure: epidemiology, pathophysiology and management.
    Desai AS; O'Gara PT
    Indian Heart J; 2005; 57(4):295-303. PubMed ID: 16350674
    [No Abstract]   [Full Text] [Related]  

  • 2. Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study.
    Krum H; Mohacsi P; Katus HA; Tendera M; Rouleau JL; Fowler MB; Coats AJ; Roecker EB; Packer M;
    Am Heart J; 2006 Jan; 151(1):55-61. PubMed ID: 16368292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients.
    Davies J; Gavin A; Band M; Morris A; Struthers A
    Br J Clin Pharmacol; 2005 May; 59(5):520-3. PubMed ID: 15842549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heart failure in the diabetic patient.
    Bell DS
    Cardiol Clin; 2007 Nov; 25(4):523-38; vi. PubMed ID: 18063157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients.
    Bell DS; Bakris GL; McGill JB
    Diabetes Obes Metab; 2009 Mar; 11(3):234-8. PubMed ID: 18564334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy.
    Botoni FA; Poole-Wilson PA; Ribeiro AL; Okonko DO; Oliveira BM; Pinto AS; Teixeira MM; Teixeira AL; Reis AM; Dantas JB; Ferreira CS; Tavares WC; Rocha MO
    Am Heart J; 2007 Apr; 153(4):544.e1-8. PubMed ID: 17383291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. When to treat the hypertensive diabetic patient.
    Fuller JH
    J Diabetes Complications; 1996; 10(3):144-5. PubMed ID: 8807461
    [No Abstract]   [Full Text] [Related]  

  • 8. The rationale and design of the Glycemic Effects in Diabetes Mellitus Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial.
    Bakris GL; Bell DS; Fonseca V; Katholi R; McGill J; Phillips R; Raskin P; Wright JT; Iyengar M; Holeslaw T; Anderson KM;
    J Diabetes Complications; 2005; 19(2):74-9. PubMed ID: 15745836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hypertension and diabetes: mechanisms of elevation of arterial pressure, physiopathologic basis of therapeutic antihypertensives].
    Mogensen CE
    Journ Annu Diabetol Hotel Dieu; 1993; ():161-88. PubMed ID: 8331863
    [No Abstract]   [Full Text] [Related]  

  • 10. When the heart runs out of heartbeats: treatment options for refractory end-stage heart failure.
    Ahmad T; Patel CB; Milano CA; Rogers JG
    Circulation; 2012 Jun; 125(23):2948-55. PubMed ID: 22689932
    [No Abstract]   [Full Text] [Related]  

  • 11. Carvedilol: use in chronic heart failure.
    Doughty RN; White HD
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):21-31. PubMed ID: 17187454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineralocorticoid receptors: an appealing target to treat coronary microvascular dysfunction in diabetes.
    Bender SB; Jia G; Sowers JR
    Diabetes; 2015 Jan; 64(1):3-5. PubMed ID: 25538279
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacological treatment and prevention of heart failure in the diabetic patient.
    Nesto RW
    Rev Cardiovasc Med; 2004; 5(1):1-8. PubMed ID: 15029109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diuretics accelerate diabetic nephropathy in hypertensive insulin-dependent and non-insulin-dependent subjects.
    Walker WG; Hermann J; Yin DP; Murphy RP; Patz A
    Trans Assoc Am Physicians; 1987; 100():305-15. PubMed ID: 3455072
    [No Abstract]   [Full Text] [Related]  

  • 15. On the antioxidant activity of carvedilol in human polymorphonuclear leukocytes in vitro and ex vivo.
    Drábiková K; Jancinová V; Nosál' R; Solík P; Murín J; Holománová D
    Neuro Endocrinol Lett; 2006 Dec; 27 Suppl 2():138-40. PubMed ID: 17159799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carvedilol versus cardioselective beta-blockers for the treatment of hypertension in patients with type 2 diabetes mellitus.
    Fardoun RZ
    Pharmacotherapy; 2006 Oct; 26(10):1491-500. PubMed ID: 16999659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    Weir RA; McMurray JJ; Puu M; Solomon SD; Olofsson B; Granger CB; Yusuf S; Michelson EL; Swedberg K; Pfeffer MA;
    Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of beta-blockers for heart failure in patients with diabetes mellitus.
    Giles TD
    Postgrad Med; 2002 Nov; 112(5 Suppl Unanswered):32-7. PubMed ID: 19667606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Place of beta blockaders in the treatment of heart failure].
    Pornin M; Van Viet H
    Ann Cardiol Angeiol (Paris); 1998 Dec; 47(10):753-6. PubMed ID: 9922855
    [No Abstract]   [Full Text] [Related]  

  • 20. Managing the patient with diabetes mellitus and heart failure: issues and considerations.
    Fonarow GC
    Am J Med; 2004 Mar; 116 Suppl 5A():76S-88S. PubMed ID: 15019865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.